Cytokines or their antagonists for the treatment of asthma
- PMID: 16840409
- DOI: 10.1378/chest.130.1.244
Cytokines or their antagonists for the treatment of asthma
Abstract
T helper (Th) type 2 cytokines, particularly interleukin (IL)-4, IL-5, and IL-13, may be important in the development of allergic asthma. Humanized monoclonal antibodies (MoAbs) against IL-5 and a recombinant human soluble IL-4 receptor (sIL-4R) have been developed as possible treatments. These approaches have not yet proven to be successful in patients with persistent asthma. This may suggest that neither IL-4 nor IL-5 is important in asthma pathogenesis. There is, however, insufficient information about the efficacy of sIL-4R and the anti-IL-5 MoAbs in asthma to draw any firm conclusions about the importance of these Th2 cytokines. Also, the administration of the potentially antiinflammatory cytokines IL-12 and interferon-gamma has not shown benefit in asthmatic patients. By contrast, the treatment of severe oral steroid-dependent asthma with soluble tumor necrosis factor-alpha receptor has demonstrated very promising results, suggesting that this cytokine plays an important role in the persistence of severe asthma.
Similar articles
-
Reassessing the Th2 cytokine basis of asthma.Trends Pharmacol Sci. 2004 May;25(5):244-8. doi: 10.1016/j.tips.2004.03.008. Trends Pharmacol Sci. 2004. PMID: 15120489 Review.
-
Cytokine antagonists for the treatment of asthma: progress to date.BioDrugs. 2009;23(4):241-51. doi: 10.2165/11317130-000000000-00000. BioDrugs. 2009. PMID: 19697966 Review.
-
Agents against cytokine synthesis or receptors.Eur J Pharmacol. 2006 Mar 8;533(1-3):289-301. doi: 10.1016/j.ejphar.2005.12.046. Epub 2006 Feb 2. Eur J Pharmacol. 2006. PMID: 16457805 Review.
-
[Inflammatory cytokines (IL-4, IL-5 and IL-13)].Nihon Rinsho. 2001 Oct;59(10):1894-9. Nihon Rinsho. 2001. PMID: 11676128 Review. Japanese.
-
Novel monoclonal treatments in severe asthma.J Asthma. 2017 Dec;54(10):991-1011. doi: 10.1080/02770903.2017.1296157. Epub 2017 Mar 13. J Asthma. 2017. PMID: 28287273 Review.
Cited by
-
The K+ channels K(Ca)3.1 and K(v)1.3 as novel targets for asthma therapy.Br J Pharmacol. 2009 Aug;157(8):1330-9. doi: 10.1111/j.1476-5381.2009.00362.x. Br J Pharmacol. 2009. PMID: 19681865 Free PMC article. Review.
-
Psychological factors in asthma.Allergy Asthma Clin Immunol. 2008 Mar 15;4(1):12-28. doi: 10.1186/1710-1492-4-1-12. Epub 2008 Mar 15. Allergy Asthma Clin Immunol. 2008. PMID: 20525122 Free PMC article.
-
Intraindividual long term stability and response corridors of cytokines in healthy volunteers detected by a standardized whole-blood culture system for bed-side application.BMC Med Res Methodol. 2012 Aug 1;12:112. doi: 10.1186/1471-2288-12-112. BMC Med Res Methodol. 2012. PMID: 22853196 Free PMC article.
-
Primary prevention of allergic diseases: current concepts and mechanisms.Allergy Asthma Clin Immunol. 2007 Dec 15;3(4):105-13. doi: 10.1186/1710-1492-3-4-105. Epub 2007 Dec 15. Allergy Asthma Clin Immunol. 2007. PMID: 20525115 Free PMC article.
-
Chemokines and their receptors as potential targets for the treatment of asthma.Br J Pharmacol. 2007 Jul;151(6):725-36. doi: 10.1038/sj.bjp.0707263. Epub 2007 Apr 30. Br J Pharmacol. 2007. PMID: 17471178 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical